TY - JOUR
T1 - Immunovascular classification of HCC reflects reciprocal interaction between immune and angiogenic tumor microenvironments
AU - Kurebayashi, Yutaka
AU - Matsuda, Kosuke
AU - Ueno, Akihisa
AU - Tsujikawa, Hanako
AU - Yamazaki, Ken
AU - Masugi, Yohei
AU - Kwa, Wit Thun
AU - Effendi, Kathryn
AU - Hasegawa, Yasushi
AU - Yagi, Hiroshi
AU - Abe, Yuta
AU - Kitago, Minoru
AU - Ojima, Hidenori
AU - Sakamoto, Michiie
N1 - Funding Information:
This work was supported by Japan Society for the Promotion of Science under grant number 17H07089 and 21K15407, by Keio University Academic Development Funds for Individual Research, and by Japan Agency for Medical Research and Development under grant numbers JP21fk0210090 and JP20ae0101020 h
Funding Information:
This work was supported by Japan Society for the Promotion of Science under grant number 17H07089 and 21K15407, by Keio University Academic Development Funds for Individual Research, and by Japan Agency for Medical Research and Development under grant numbers JP21fk0210090 and JP20ae0101020 We thank all members in Yonken in Department of Pathology, Keio University School of Medicine, for their supports in histological analysis. We also thank members in Core Facility, Collaborative Research Resources, Keio University School of Medicine, for their supports in Sanger sequencing.
Funding Information:
Dr. Sakamoto received grants from Eisai and Cytlimic.
Publisher Copyright:
© 2021 American Association for the Study of Liver Diseases.
PY - 2022/5
Y1 - 2022/5
N2 - Background and Aims: Immune cells and tumor vessels constitute important elements in tumor tissue; however, their detailed relationship in human tumors, including HCC, is still largely unknown. Consequently, we expanded our previous study on the immune microenvironment of HCC and analyzed the relationship among the immune microenvironment, inflammatory/angiostatic factor expression, angiogenic factor expression, and tumor vessel findings, including vessels encapsulating tumor clusters (VETC) and macrotrabecular-massive (MTM) patterns. Approach and Results: We classified HCC into four distinct immunovascular subtypes (immune-high/angiostatic [IH/AS], immune-mid/angio-mid [IM/AM], immune-low/angiogenic [IL/AG], and immune-low/angio-low [IL/AL]). IH/AS, IM/AM, and IL/AG subtypes were associated with decreasing lymphocytic infiltration and increasing angiogenic factor expression and VETC/MTM positivity, reflecting their reciprocal interaction in the tumor microenvironment of HCC. IL/AG subtype was further characterized by CTNNB1 mutation and activation of Wnt/β-catenin pathway. IL/AL subtype was not associated with increased lymphocyte infiltration or angiogenic factor expression. Prognostically, IH/AS subtype and VETC/MTM positivity were independently significant in two independent cohorts. Increased angiogenic factor expression was not necessarily associated with VETC/MTM positivity and poor prognosis, especially when inflammatory/angiostatic milieu coexisted around tumor vessels. These results may provide insights on the therapeutic effects of immunotherapy, antiangiogenic therapies, and their combinations. The potential of evaluating the immunovascular microenvironment in predicting the clinical effect of these therapies in nonresectable HCC needs to be analyzed in the future study. Conclusions: HCC can be classified into four distinct immunovascular subtypes (IH/AS, IM/AM, IL/AG, and IL/AL) that reflect the reciprocal interaction between the antitumor immune microenvironment and tumor angiogenesis. In addition to its clinicopathological significance, immunovascular classification may also provide pathological insights on the therapeutic effect of immunotherapy, antiangiogenic therapy, and their combination.
AB - Background and Aims: Immune cells and tumor vessels constitute important elements in tumor tissue; however, their detailed relationship in human tumors, including HCC, is still largely unknown. Consequently, we expanded our previous study on the immune microenvironment of HCC and analyzed the relationship among the immune microenvironment, inflammatory/angiostatic factor expression, angiogenic factor expression, and tumor vessel findings, including vessels encapsulating tumor clusters (VETC) and macrotrabecular-massive (MTM) patterns. Approach and Results: We classified HCC into four distinct immunovascular subtypes (immune-high/angiostatic [IH/AS], immune-mid/angio-mid [IM/AM], immune-low/angiogenic [IL/AG], and immune-low/angio-low [IL/AL]). IH/AS, IM/AM, and IL/AG subtypes were associated with decreasing lymphocytic infiltration and increasing angiogenic factor expression and VETC/MTM positivity, reflecting their reciprocal interaction in the tumor microenvironment of HCC. IL/AG subtype was further characterized by CTNNB1 mutation and activation of Wnt/β-catenin pathway. IL/AL subtype was not associated with increased lymphocyte infiltration or angiogenic factor expression. Prognostically, IH/AS subtype and VETC/MTM positivity were independently significant in two independent cohorts. Increased angiogenic factor expression was not necessarily associated with VETC/MTM positivity and poor prognosis, especially when inflammatory/angiostatic milieu coexisted around tumor vessels. These results may provide insights on the therapeutic effects of immunotherapy, antiangiogenic therapies, and their combinations. The potential of evaluating the immunovascular microenvironment in predicting the clinical effect of these therapies in nonresectable HCC needs to be analyzed in the future study. Conclusions: HCC can be classified into four distinct immunovascular subtypes (IH/AS, IM/AM, IL/AG, and IL/AL) that reflect the reciprocal interaction between the antitumor immune microenvironment and tumor angiogenesis. In addition to its clinicopathological significance, immunovascular classification may also provide pathological insights on the therapeutic effect of immunotherapy, antiangiogenic therapy, and their combination.
UR - http://www.scopus.com/inward/record.url?scp=85120883504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120883504&partnerID=8YFLogxK
U2 - 10.1002/hep.32201
DO - 10.1002/hep.32201
M3 - Article
C2 - 34657298
AN - SCOPUS:85120883504
SN - 0270-9139
VL - 75
SP - 1139
EP - 1153
JO - Hepatology
JF - Hepatology
IS - 5
ER -